Day: July 22, 2025

– Video webcast now available on-demand  THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. For the event, Mr. Hauser dove deeper into his dedication to the Company, how he got to where he is today, and provided insight into why he is passionate about the Company’s innovative technology. The on-demand video webcast is now available on the Virtual Investor website as well as the Events page under the Investors section of the Company’s website...

– Video webcast now available on-demand Carlsbad, CA, July 22, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced JD Finley Chief Executive Officer of Palisade Bio, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. As part of the event, Mr. Finley dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company’s programs in development. The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page under the Investors section of...

– Video webcast now available on-demand  HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Founder, President, CEO and Chairman of Moleculin, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. As part of the segment, Mr. Klemp dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company’s programs in development. The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page of the Investors section of the Company’s website (moleculin.com). About Moleculin...

NINGDE, China, July 22, 2025 (GLOBE NEWSWIRE) — Oriental Rise Holdings Limited (Nasdaq: ORIS) (“Oriental Rise” or the “Company”), an integrated supplier of white- and black-tea products in mainland China, today announced the pricing of its public offering (the “Offering”) of up to 14,800,000 Units on a best-efforts basis at a price of US$0.4681 per Unit. Each Unit consists of one Ordinary Share (or one Pre-Funded Warrant to purchase one Ordinary Share in lieu thereof), par value US$0.0008 per share, and one Common Warrant to purchase one Ordinary Share. Each Common Warrant is exercisable immediately on the date of issuance at an exercise price of US$0.4681 per share and will expire five years from the date of issuance. The Common Warrants may, at any time following the closing of this Offering and in the holders’ sole discretion,...

Performed by Dr. Sudhir Srivastava utilizing the Company’s SSi Mantra 3 surgical robotic system Remotely conducted from IRCAD in Strasbourg, France, at an unprecedented distance of more than 4,000 miles to the operating room at SAIMS in Indore, India FORT LAUDERDALE, Fla., July 22, 2025 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company’s Chairman of the Board and Chief Executive Officer, Dr. Sudhir Srivastava, M.D., successfully completed the world’s first intercontinental robotic cardiac telesurgery on July 19, 2025, utilizing the Company’s SSi Mantra 3 surgical robotic system. Dr. Srivastava performed...

Join Sysco Chairman and CEO Kevin Hourican, elected officials and customers at the opening of the 6th operating facility in Florida PLANT CITY, Fla., July 22, 2025 (GLOBE NEWSWIRE) — Today, Sysco Corporation, the leading global foodservice distribution company, is inviting media to attend a press conference and tour celebrating the grand opening of our newest distribution center, Sysco Tampa Bay. WHAT: Sysco Tampa Bay grand opening, ribbon-cutting, press conference and tourTIME AND DATE: 9:30 a.m. EST on July 24, 2025WHERE: 475 Charlie Taylor Road, Plant City, Fla., 33566KEY SPEAKERS: Sysco Chairman and CEO Kevin HouricanFlorida State Sen. Jay CollinsPlant City Mayor Nate KiltonFlorida State Commerce Department representative Madison LawsonSysco Region President Jane GroutRSVP AND QUESTIONS: media@sysco.com Sysco invites media...

WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd (“Yorkville”).   The extinguishment of this convertible note, dated January 16, 2025, has cleared the Company’s outstanding debt obligations to Yorkville. David Mehalick, CEO of Coeptis Therapeutics Holdings, Inc., stated, “The extinguishment of these outstanding debt obligations strengthens the Company’s capital structure and positions us well to pursue our long-term goals.” Management notes that a streamlined capital structure free from the weight of unnecessary outstanding obligations will help the Company navigate its proposed strategic addition of operations in...

Ra’anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen contact—reinforcing the product’s potential as a barrier-forming treatment for allergic rhinitis. The evaluation was led by Professor Fabio Sonvico from the Department of Food and Drug at the University of Parma, a leading authority in intranasal and pulmonary drug delivery and a member of Polyrizon’s...

Project advances regional water resilience and environmental restoration efforts IRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) — Shimmick Corporation (“Shimmick” or the “Company”) (Nasdaq: SHIM), a national leader in complex infrastructure solutions, has been awarded a $51 million contract by the Stockton East Water District (SEWD) for the Bellota Weir Modifications project in Stockton, California. The project includes the construction of a new inflatable Obermeyer gate weir across Mormon Slough, a surface water intake with cylindrical fish screens, a vertical slot fish ladder featuring lamprey ramps, and a gravity flow conveyance system comprising multiple 54-inch pipelines. Additional features include a fish exclusion embankment, a low-permeability cutoff wall in the Old Calaveras River, and site improvements designed to support...

BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, August 5, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the second quarter 2025. Live audio of the webcast will be accessible on Day One’s Events on the Day One Media & Investors page. An archived version of the webcast will be available for replay on the News & Events section of the Day One Media & Investors page for 30 days following the event. About Day One Biopharmaceuticals Day One Biopharmaceuticals believes when it comes to pediatric...